Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Schiff, R"'
Autor:
Forsyth, F, Brimicombe, J, Cheriyan, J, Edwards, D, Hobbs, FDR, Jalaludeen, N, Mant, J, Pilling, M, Schiff, R, Taylor, CJ, Zaman, MJ, Deaton, C, Chakravorty, M, Maclachlan, S, Kane, E, Odone, J, Thorley, N, Borja-Boluda, S, Wellwood, I, Sowden, E, Blakeman, T, Chew-Graham, C, Hossain, M, Sharpley, J, Gordon, B, Taffe, J, Long, A, Aziz, A, Swayze, H, Rutter, H, Schramm, C, MacDonald, S, Papworth, H, Smith, J, Needs, C, Cronk, D, Newark, C, Blake, D, Brown, A, Basuita, A, Gayton, E, Glover, V, Fox, R, Crawshaw, J, Ashdown, H, A'Court, C, Ayerst, R, Hernandez-Diaz, B, Knox, K, Wooding, N, Wanninayake, S, Keast, C, Jones, A, Brown, K, Gaw, M, Thomas, N, Dixon, S, Angeleri-Rand, E
Publikováno v:
ESC Heart Failure, Vol 8, Iss 6, Pp 4562-4571 (2021)
ESC Heart Failure
ESC Heart Failure
Funder: NIHR Cambridge Clinical Research Facility
Aims: Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure (HF), but low awareness and diagnostic challenges hinder identification in primary care. Our ai
Aims: Heart failure with preserved ejection fraction (HFpEF) accounts for half of all heart failure (HF), but low awareness and diagnostic challenges hinder identification in primary care. Our ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a0836e0e3864eb5645058ab1f34911
https://doi.org/10.1002/ehf2.13612
https://doi.org/10.1002/ehf2.13612
Background: 64 million pharmacy filled multicompartment medication compliance aids (MCAs) are dispensed by pharmacies in England each year as a method to improve medication adherence. Despite the widespread use of MCAs and evidence that their use may
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::944d7a5ec2345f5c895519889de628f2
https://doi.org/10.22541/au.162483795.57322467/v1
https://doi.org/10.22541/au.162483795.57322467/v1
Autor:
Britta Weigelt, Resel Pereira, C. Kent Osborne, Rinath Jeselsohn, Jiangang Liu, Vidyalakshmi Sethunath, Jamunarani Veeraraghavan, Rachel Schiff, Lanfang Qin, Luca Malorni, Pier Selenica, Carmine De Angelis, Xiaoyong Fu, Ilenia Migliaccio, David N Brown, Susan G. Hilsenbeck, Sarmistha Nanda, Joshua Donaldson, Valerie M. Jansen, Sara A. Hurvitz, Agostina Nardone, Dennis J. Slamon, Ben Ho Park, Tao Wang, Jorge S. Reis-Filho, Lacey M. Litchfield, C. Guarducci, Matteo Benelli, Maria Letizia Cataldo, Mothaffar F. Rimawi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 27, iss 17
Purpose: Cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors (CDK4/6i) are highly effective against estrogen receptor–positive (ER+)/HER2− breast cancer; however, intrinsic and acquired resistance is common. Elucidating the molecular features of
Cancer immunology is the most rapidly expanding field in cancer research, with the importance of immunity in cancer pathogenesis now well accepted including in the endocrine-related cancers. The immune system plays an essential role in the developmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d0edccc5d69e4f464abc44f3066a1e
http://hdl.handle.net/11588/879945
http://hdl.handle.net/11588/879945
Autor:
Rachel Schiff, Mothaffar F. Rimawi, Matthew P. Goetz, Jorge S. Reis-Filho, Ting Wang, Britta Weigelt, Carolina Gutierrez, CK Osborne, Aleix Prat, Suzanne A. W. Fuqua, Antonio C. Wolff, R. Mao, Jamunarani Veeraraghavan, Andres Forero, Anna C. Pavlick, Paolo Nuciforo, Ingrid A. Mayer, C. De Angelis, SG Hilsenbeck, Jenny C. Chang, Ian E. Krop, Rita Nanda, Sabrina Herrera, Alejandro Contreras
Publikováno v:
Ann Oncol
BACKGROUND: HER2-positive (+) breast cancers, defined by HER2 overexpression and/or amplification, are often addicted to HER2 to maintain their malignant phenotype. Yet, some HER2+ tumors do not benefit from anti-HER2 therapy. We hypothesize that HER
Autor:
Alshad S. Lalani, Sarmistha Nanda, Mario Giuliano, Tamika Mitchell, Jamunarani Veeraraghavan, Carmine De Angelis, C. Kent Osborne, Martin Shea, Chandandeep Nagi, Sepideh Mehravaran, Lanfang Qin, Kristina Goutsouliak, Irmina Diala, Robert Davis, Mothaffar F. Rimawi, Tao Wang, Susan G. Hilsenbeck, Vidyalakshmi Sethunath, Rachel Schiff, Resel Pereira, Carolina Gutierrez
Publikováno v:
NPJ Breast Cancer
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Lapatinib (L) plus trastuzumab (T), with endocrine therapy for estrogen receptor (ER)+ tumors, but without chemotherapy, yielded meaningful response in HER2+ breast cancer (BC) neoadjuvant trials. The irreversible/pan-HER inhibitor neratinib (N) has
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edaed2ac904def2f8e1fb6bad3d4e4f2
http://hdl.handle.net/11588/857292
http://hdl.handle.net/11588/857292
Autor:
Mothaffar F. Rimawi, Grazia Arpino, Angelo Di Leo, Fabiola Giudici, Pietro De Placido, Sergio Venturini, Mario Giuliano, Lajos Pusztai, Sabino De Placido, Lucia Del Mastro, Guy Jerusalem, Daniele Generali, Michelino De Laurentiis, Fabio Puglisi, Francesco Schettini, Carla Rognoni, Aleix Prat, Benedetta Conte, Rachel Schiff, Mariavittoria Locci, Pierfranco Conte
Publikováno v:
Cancers
Cancers, Vol 13, Iss 1458, p 1458 (2021)
Cancers, Vol 13, Iss 1458, p 1458 (2021)
Simple Summary Hormone receptor-positive (HR+)/HER2-negative is the most frequent subgroup of metastatic breast cancer (MBC). Important therapeutic advances in the treatment of this tumor type have been observed in the last 20 years, with the approva
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77086d2ad8b624c9d548593716a07171
http://hdl.handle.net/11390/1206209
http://hdl.handle.net/11390/1206209
Autor:
Aranzazu Fernandez-Martinez, Barbara Adamo, Blanca Gonzalez-Farre, Lisa A. Carey, Francesco Schettini, Benedetta Conte, Charles M. Perou, Jamunarani Veeraraghavan, Jan C. Brase, Sabino De Placido, Tomás Pascual, Mariavittoria Locci, Pierfranco Conte, Patricia Villagrasa, Montserrat Muñoz, Sonia Pernas, Fara Brasó-Maristany, Olga Martínez, Patricia Galván, Maria Vidal, Mothaffar F. Rimawi, C. Kent Osborne, Carla Rognoni, Gaia Griguolo, Rachel Schiff, Nuria Chic, Valentina Guarneri, Aleix Prat
Publikováno v:
Cancer Treat Rev
Background: HER2-positive (HER2+) breast cancer (BC) comprises all the four PAM50 molecular subtypes. Among these, the HER2-Enriched (HER2-E) appear to be associated with higher pathological complete response (pCR) rates following anti-HER2-based reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::456360a8625da925d93580bf31f87b0f
https://europepmc.org/articles/PMC7230134/
https://europepmc.org/articles/PMC7230134/
Autor:
Alice Loo, Piotr Stepien, Avery S. Feit, David M. Sabatini, Johann Bergholz, Walter Michael, Monther Abu-Remaileh, Christopher Thomas Brain, Rinath Jeselsohn, Baishan Jiang, Deborah Butter, Michael D. Cameron, Carmine DeAngelis, Wojciech Michowski, Rachel Schiff, Deborah A. Dillon, Karolina Maria Nowak, Iga Stukan, Bojana Jovanovic, Jean J. Zhao, Tobias Otto, Nathanael S. Gray, Maria Ericsson, Anne Fassl, Piotr Sicinski, Ralph Tiedt, Myles Brown, Kornelia Polyak, Qing Sheng
Publikováno v:
Science Advances
This study presents strategies to render triple-negative breast cancers sensitive to CDK4/6 inhibitors.
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor–positive breast cancers. In contr
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor–positive breast cancers. In contr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc4815f131efc64eea3d77fec1fe579f
http://hdl.handle.net/11588/857297
http://hdl.handle.net/11588/857297
Autor:
C. Kent Osborne, Vidyalakshmi Sethunath, Rachel Schiff, Mothaffar F. Rimawi, Jamunarani Veeraraghavan, Carmine De Angelis, Kristina Goutsouliak
Publikováno v:
Nat Rev Clin Oncol
Advances in HER2-targeted therapies have improved the survival of patients with HER2-positive breast cancer. The standard-of-care treatment for localized disease has been chemotherapy and 1 year of adjuvant HER2-targeted therapy, typically with the a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b7964be3e4fdc804b203e88021196b
http://hdl.handle.net/11588/847721
http://hdl.handle.net/11588/847721